BioTransplant +++Smallcap mit Phantasie+++ - 500 Beiträge pro Seite

[m.lynched]

BioTransplant (BTRN, 900681) entwickelt die sogenannte ImmunoCognance-Technologie, die langfristig Abwehrreaktionen
auf transplantierte Zellen, Gewebe und Organe durch eine Reprogrammierung des Immunsystems verhindern soll.
Durch eine Kombination von fremden und körpereigenen Zellen werden fremde Gewebe oder Organe nicht mehr als
solche erkannt und nicht vom Immunsystem angegriffen. Die in der Transplantationschirurgie gefürchtete Abstoß-
Reaktion bleibt aus. So müssen nach schweren Transplantationen nicht mehr lebenslang Immunsupressiva verabreicht
werden und die Patienten gesunden schneller, was auch die Transplantationskosten insgesamt senkt.
In der Krebstherapie kann umgekehrt das Immunsystem gezielt auf Tumorzellen ausgerichtet werden. Das auf
dieser Technik basierende Hauptstandbein von BioTransplant, MEDI-507, befindet sich in Phase II und wird bei
Knochenmarktransplantationen von Leukämiepatienten eingesetzt. MEDI-507 gehört zur Gruppe der monoklonalen
Antikörper und wird von MedImmune entwickelt und in den Markt eingeführt werden. BioTransplant erhält neben
Meilensteinzahlungen und Lizenzgebühren außerdem Umsatzbeteiligungen und darf MEDI-507 in den AlloMune-
und XenoMune-Systemen verwenden.

AlloMune (Phase I/II) ist ein verwandtes Verfahren, das u.a. bei Nierentransplantationen zum Einsatz kommen soll,
um die erwähnten Immunreaktionen zu verhindern. Erforscht wird außerdem die Möglichkeit, mit AlloMune bestimmte
Formen von Blutkrebs zu behandeln, die bisher als nicht therapierbar gelten. Am 15. Mai wurden Ergebnisse von klinischen
Versuchen vorgestellt, die äußerst ermutigend sind. Bislang setzt die Transplantation von Knochenmark wegen der
Autoimmunreaktionen eine große genetische Übereinstimmung von Spender und Empfänger voraus. AlloMune zeigte
bei den meisten Patienten die gewünschte Wirkung und konnte bereits auftretende Abstoßungsreaktionen eindämmen.
AlloMune hat von der FDA bereits den FastTrackStatus erhalten.

Auch die XenoMune-Technologie befindet sich bereits in der klinischen Testphase. Mit XenoMune ist ungeheuer viel
Phantasie verbunden, denn diese Technologie soll die Transplantation von Schweineorganen ermöglichen! Wichtigster
Kooperationspartner für die XenoMune-Technologie ist Novartis. Dieses Abkommen garantiert BTRN Lizenzgebühren,
Forschungshilfen und Meilensteinzahlungen bis zu 36M $.

Jüngste, durchaus spektakulär zu nennende Zwischenberichte haben bereits zu einem erheblichen Kursaufschwung
geführt. Am 6. Juni wurde bekannt, daß 10 Diabetiker durch eine Transplantation von Bauchspeicheldrüsenzellen
insulinunabhängig wurden!

Die Marktkapitalisierung beträgt zur Zeit 112M $.
Princeton, New Jersey, May 16 (Bloomberg Data) -- BioTransplant Inc. (BTRN US) was reiterated ``buy`` by analyst Kellie Seringer at Evolution Capital. The target price is $30 per share.



Ich möchte darauf hinweisen, daß die Produktpipeline offensichtlich nicht allzu breit ist und BTRN allein deshalb schon als spekulative
Anlage betrachtet werden sollte. Gleichwohl scheint aufgrund der Phantasie, die in dieser Aktie steckt, eine überdurchschnittliche
Wertentwicklung möglich.

Kann jemand Angaben über evtl. Konkurrenten und Umsatzpotential machen? Angenommen, Transplantationen von Schweineorganen werden in absehbarer Zeit möglich,
wieviel Umsatz läßt sich damit erzielen?

Gruß, ml

[m.lynched]

ein paar ergänzende Anmerkungen zur XenoMune-Technologie:

Die Transplantation von tierischen Zellen, Geweben oder Organen hat viele Kritiker, die u.a. folgende Argumente ins Feld führen:
Die Xenotransplantation sei mit unkalkulierbaren Risiken verbunden, da eine Übertragung von Viren nicht auszuschließen sei. Als
Präzedenzfälle werden Ebola, Schweinepest, Hühnergrippe und HIV betrachtet. Außerdem wird der ökonomische Nutzen bezweifelt.
Ein Schwein vollständig auf bekannte Viren und Mikroorganismen zu untersuchen (man braucht ein nahezu steriles Schwein!)
koste zur Zeit 25 - 100000 $ und alles in allem sei zweifelhaft, ob Xenotransplantationen nicht teurer als herkömmliche
Transplantationen (durchschnittlich 300000$) würden.
(Wer sich ausführlich über die Vorbehalte gegen die Xenotransplantation informieren möchte: http://www.crt-online.org/)

Interessant ist ein ökonomisches Argument, das auf der o.a. Homepage angeführt wird:
"A 1996 Institute of Medicine report predicts that xenotransplantation will push annual transplant cost from $3 billion to $20.3 billion. These costs are beyond the means of a majority of Americans and an already overburdened health care system."
Da offensichtlich eine starke Nachfrage vorhanden ist (wie nicht nur diese Zahlen, sondern auch die regelmäßigen Meldungen über
Organhandel belegen), spielt das Kostenargument wohl eine untergeordnete Rolle, meine ich.
Ich kann nicht sagen, wie sich diese 20.3 B $ zusammensetzen. Jedenfalls würde sich der Jahresumsatz auf mehrere Milliarden $ belaufen.
Um diesen Markt konkurrieren derzeit die folgenden Firmen:


Alexion Pharmaceuticals
www.alexionpharmaceuticals.com

Algenix
www.algenix.com

Baxter Healthcare/Nextran
www.baxter.com

Biohybrid

Biotransplant
www.biotransplant.com

Circe Biomedical
www.circebiomedical.com

Cytotherapeutics, Inc.

Diacrin
www.diacrin.com

Excorp Medical

Genzyme
www.genzyme.com

Infigen
www.infigen.com

Neocrin

Novartis/Imutran
www.novartis.org

PPL Therapeutics/Geron Biomed
www.ppl-therapeutics.com
www.geron.com

[m.lynched]

Monday August 28 1:40 PM ET
New Breed of Pig May Allow Animal-Human Transplants


By Maggie Fox, Health and Science Correspondent

WASHINGTON (Reuters) - Corporate researchers said on Monday they
had bred a pig that does not seem to transmit potentially dangerous viruses to
human cells, and said it might be a way to make animal-to-human transplants
safe.

Charlestown, Massachusetts-based BioTransplant Inc. (NasdaqNM:BTRN
- news) said its miniature swine carried the viruses, but for some reason did
not transmit them to human cells the way normal pigs do.

It hopes it can now genetically engineer its miniature pigs so that human
bodies will accept their tissue and organs.

``What we are hoping to do with it is build this inbred herd as a potentially
safer source of cells, tissues and organs for xenotransplants (animal-to-human transplants),`` Elliot Lebowitz,
president and chief executive officer of BioTransplant, said in a telephone interview.

``We are hoping that we can save a lot of lives in a safer way and also reduce the healthcare costs, which are
horrendous for end-stage organ disease.``

More than 70,000 Americans and hundreds of thousands of people around the world are on waiting lists for
new organs, but there are not nearly enough to go around. An estimated 10 people die every day in the United
States alone while waiting for a heart, liver, kidney or other organ. [Soviel zum Potential...]

Pigs are considered a possible good source for organs, as they are readily available, easily bred and are about
the same size as people.

But there are two huge obstacles. Like most other animals including humans, pigs carry viruses called
endogenous retroviruses. These viruses have incorporated themselves into the genome, cannot be removed and
are infectious.

And animal cells have a molecule on their surface that causes the human immune system to recognize them as
foreign and reject them. Transplanted animal organs quickly die in the human body.

Earlier this month, Daniel Salomon of the Scripps Institute in California reported that he had shown that the pig
viruses, known as porcine endogenous retroviruses (PERVs), can infect human cells. He said earlier studies that
suggested PERVs do not infect people may not have looked in the right places.

Lebowitz said his company hired one of the discoverers of PERVs, Clive Patience, to try and get around this
problem.

``We have shown that it is possible to create pigs which will not have human infectivity from PERVs,`` Lebowitz
said.

``It appears that these animals don`t contain replication-competent PERV in human cells. We don`t know why.``

Patience was scheduled to present the findings to a transplant conference in Rome on Monday and was not
immediately reachable for comment.

Lebowitz said the miniature pigs, created for BioTransplant by a local supplier of animals for medical research,
were highly inbred and this could be the reason their viruses could not be transmitted to human cells at least in
the laboratory.

The company has not tested the pig cells in living animals to see if they can be infected, but said it did incubate
human cells with cells from normal pigs and they became infected.

The company has licensed its technology to Swiss pharmaceutical giant Novartis (NOVZn.S), Lebowitz said.

Several companies are working to create pigs that can be used for animal-to-human transplants, called
xenotransplants. British scientists at PPL Therapeutics (PTH.L), associated with the Roslin Institute in
Edinburgh where Dolly the sheep was cloned, have cloned pigs with the aim of creating animals suitable for
xenotransplants.

But U.S.-based Geron (NasdaqNM:GERN - news) said it was reducing funding to its Roslin subsidiary, Geron
Bio-Med, for work on cloning genetically engineered pigs.

[m.lynched]

nach wie vor hochspekulativ

[m.lynched]

Noch ein Kommentar zur Nachricht von gestern:

Biotransplant sees pork-belly future for medicine
By Tom Davey
Redherring.com, August 29, 2000
Many of the 72,000 Americans awaiting organ transplants may be turning to swine for hearts, kidneys, and other organs. A small biotech concern that has been researching "xenotransplantation" -- the field of transplanting organs from other species into humans -- claims to have achieved a milestone that may result in tests of pig organ transplants to humans within the next two years.

A scientist from Biotransplant (Nasdaq: BTRN) revealed Monday that a pig virus known as the porcine endogenous retrovirus, which is transmitted when pig tissue is transplanted to humans, has been genetically altered so that it cannot reproduce in humans, effectively rendering the disease harmless. Dr. Clive Patience, principal scientist at Biotransplant, disclosed his findings Monday in Rome at the International Congress of the Transplantation Society.

Biotransplant has a development agreement with Novartis, whereby the Swiss drug company shoulders some development costs in exchange for the rights to market the animal`s organs. Biotransplant CEO Elliot Lebowitz declined to say what percentage of revenues would go to Biotransplant, but he claims commercialization has the "potential for generating $100 million in annual cash flow" for the 70-person company.

However, don`t expect those numbers anytime soon. Earlier studies have shown no ill effects on human health from the transmission of pig viruses, but their potential for harm has been one reason xenotransplantation isn`t ready for prime time. An even larger stumbling block has been the human immune system`s rejection of organs from other species.

[...]

[m.lynched]

Auf dem Kongreß in Rom wurden heute außerdem äußerst zufriedenstellende Ergebnisse einer Studie bekannt, die das gemeinsam mit MedImmune entwickelte MEDI-507 / BTI-322 betreffen:

BioTransplant Presents Positive Safety Data for BTI-322 Monoclonal Antibody in Adult Liver Transplant Patients
- Phase I/II Study Results Presented Today at the International Congress of The Transplantation Society, Rome, Italy -
CHARLESTOWN, Mass., Aug. 29 /PRNewswire/ -- BioTransplant Incorporated (Nasdaq: BTRN - news) and its collaborators from the Liver Transplant Program at St. Luc University Hospital in Brussels today announced the results of a phase I/II study demonstrating that adding the company`s BTI-322 monoclonal antibody to a commonly used immunosuppressive therapy, including Prograf® (tacrolimus), reduced the incidence of rejection in human liver transplantation in the immediate post-operative period by 70% compared to Prograf® protocol alone.

The study, ``One Year Results of Tacrolimus (TAC) and Anti-CD2 Antibody (BTI-322) In Adult Liver Transplantation,`` was presented today at the International Congress of the Transplantation Society, Rome, Italy, by Jan Lerut, MD. The results of this 40-patient prospective randomized study build on Dr. Lerut`s previous work with BTI-322 and further demonstrate the antibody`s potential safety and efficacy in treating adult liver transplant recipients.

``Patients receiving BTI-322 in addition to the Prograf® regimen showed a significantly lower incidence of histological rejections despite lower Prograf® dosing,`` noted Dr. Lerut. ``The combined use of these therapies appears to be safe in liver transplantation and there were no additional side effects due to the addition of BTI-322. Decreasing the initial dosing of immunosuppressive drugs may be possible by adding early treatment with BTI-322.``

BTI-322 is a murine monoclonal antibody discovered at the Catholic University of Louvain, Belgium. It has been tested extensively with encouraging preclinical and clinical results in kidney transplantation and Graft versus Host Disease (GvHD). MEDI-507, a humanized version of BTI-322, is being developed by MedImmune in collaboration with BioTransplant. MEDI-507 is currently in Phase II clinical trials for treatment of GvHD, a frequent and often fatal outcome of bone marrow transplantation. GvHD occurs when donor cells in a bone marrow transplant attack the tissue of the recipient. MEDI-507 is also being evaluated for treatment of psoriasis [Schuppenflechte].

BioTransplant, Incorporated utilizes its proprietary technologies to re-educate the body`s immune responses to allow tolerance of foreign cells, tissues and organs. Based on this technology, the Company is developing a portfolio of products for application in a range of medical conditions, including organ and tissue transplantation, and treatment of cancer and autoimmune diseases, for which current therapies are inadequate. BioTransplant`s products under development are intended to induce long-term functional transplantation tolerance in humans, increase the therapeutic benefit of bone marrow transplants, and reduce or eliminate the need for lifelong immunosuppressive therapy.

SOURCE: BioTransplant Incorporated

[Bruder_Jeremias]

z. Zt. 16 1/16 $ in USA, in D unter WKN 900681 zu 16,50€! zu haben

Gruß Jo

[m.lynched]

BASEL, Switzerland, Sept 26 (Reuters) - Swiss health care group Novartis AG and U.S.-based BioTransplant have agreed to set up a new company that will research xenotransplantation, Novartis said in a statement on Tuesday.

Xenotransplantation is the controversial science of transferring cells, tissues and organs from one species to another. It has made media headlines primarily due to its attempts to use pig organs in humans amid a shortage of donor organs from other people.

Novartis said the field "has the potential to provide a lifeline for thousands of people waiting for an organ transplant, many of whom will die before an organ becomes available".

Novartis shares were down two Swiss francs to 2,668 around 1405 GMT in a weaker Swiss market. BioTransplant shares were up 50 cents at $14.

Novartis will own 67 percent of the company and BioTransplant 33 percent. The Boston-based firm will start operations on January 1, 2001. BioTransplant Chief Scientific Officer Julia Greenstein will head the new company.

A separate Novartis unit, Imutran Ltd, will also be wrapped into the new company as the partners combine their individual expertise.

Novartis will get the rights to commercialisation of research from the new company, while BioTransplant will get royalty payments from Novartis sales.

Greenstein said that her company and Novartis had been examining different but complementary ways of overcoming the problem of recipients` rejecting transplants.

"The combination of Novartis`s expertise in immunosupression and transgenic pigs with BioTransplant`s tolerance induction programme and inbred miniature swine will provide a leading platform on which to further develop this potentially life-saving technology," she said.

Novartis`s research chief, Paul Herrling, said the move to join forces made sense. "By joining the two approaches, we hope to bring forward the day when xenotransplantation will become a clinical reality," he said.

BioTransplant will continue to work independently on tolerance reduction in allotransplantation, the statement said.

[m.lynched]

250% seit Ende Mai - jetzt wird selbst Greenpeace neugierig!

Firms produced "human-pig" hybrid - Greenpeace
By Mark John

BERLIN, Oct 5 (Reuters) - Two firms seeking a patent on an embryo cloning process have performed an experiment in which they created a ``human-pig`` hybrid embryo, environmental lobby group Greenpeace said on Thursday.

A spokeswoman for the companies involved in the patent application confirmed that laboratory cells of human origin had been used in the experiment but denied that what resulted was a human hybrid, and said Greenpeace had misunderstood the case.

Greenpeace`s German branch published extracts of what it said was the application made to the European Patent Office in Munich by U.S.-based BioTransplant (NasdaqNM:BTRN - news) and Australian firm Stem Cell Sciences.

The alleged extracts made reference to an experiment fusing parts of human and pig cells in a technique known as ``nuclear transfer`` which has already been used in cloning pigs and in making Dolly the sheep, the first adult mammal ever cloned.

``The application shows that the firms have already transferred cell nuclei from human foetuses to egg cells from pigs and cultivated the resulting embryos for around a week in the laboratory,`` Greenpeace said in a statement.

``Society should not reward these Frankenstein scientists with patents,`` it added, noting however that loopholes in European Union patent guidelines restricting such processes on human embryos meant the request stood a good chance of success.

A U.S. spokeswoman for both companies said Greenpeace`s interpretation of the experiment as wrong.

``A human foetus cell was not used in the experiment,`` Patricia Dimond told Reuters.

``The source of the cell was a laboratory cell line of human origin. It was an aneuploid cell, which means it was totally incapable of creating a human being. It was experimentally impossible to create a hybrid pig-human organism,`` she said.

The European Patent Office said it could not discuss the content of any patent request awaiting assessment but confirmed the two firms had filed an application to it.


ORGAN TRANSPLANTS

Despite the denial that a human hybrid was created in the lab, the experiment may be seen by some as the latest example of biotechnology firms entering ethical grey zones.

U.S. doctors last week used stem cells from the umbilical cord of a baby boy, Adam Nash, whose embryo was chosen to save his six-year-old sister Molly, suffering from a blood disease.

It prompted accusations that scientists were ``playing God`` by creating ``designer babies`` free of blemishes, particularly because several other fertilised embryos -- Adam`s potential siblings -- were disposed of after not being chosen. Others hailed the operation as a medical wonder.

Nuclear transfer is seen offering huge benefits in the area of animal-to-human transplants by developing animals whose tissues and organs can be grafted into humans without risk of infection.

Scientists at the Massachusetts-based biotech company Advanced Cell Technology said two years ago they had fused human cells into cow eggs and let them grow as an embryo for a few days, provoking headlines that a ``human-cow`` had been created.

The company said its aim was to grow organs and tissues in the lab for transplant.

[m.lynched]

... und noch ein paar Details, was man tatsächlich vorhat.

Firms act to patent "human-pig" hybrid cells
(UPDATE: Recasts with quotes from companies, background, previous BERLIN)

By Maggie Fox, Health and Science Correspondent

WASHINGTON, Oct 5 (Reuters) - Two firms trying to find alternatives for organ transplants said on Thursday they had applied to patent a cloning process in which they fused human and pig cells.

The environmental group Greenpeace attacked the researchers as ``Frankenstein scientists,`` prompting the companies to deny they were trying to create a half-human, half-pig creature.

They said they were looking for ways to advance therapeutic cloning, which would involve taking a patient`s own cells and growing them in the laboratory to create a source of stem cells or ``master cells,`` which could then be developed into tissue or organs for transplant.

Instead of waiting in line for an organ donor, thousands of patients could, in theory, get transplants taken from their own cells. They would not need the drugs now used to suppress their immune systems so their bodies do not reject the transplant.

Therapeutic cloning is in itself controversial, with opponents saying such creation of a human embryo for any reason is unethical. But scientists and others who support it say the mass of cells that would be created would not be an embryo in any real sense and would be a valuable medical tool.

``We support the prospect of human therapeutic cloning,`` Peter Mountford, chief executive officer of Melbourne, Australia-based Stem Cell Sciences, told Reuters in a telephone interview.

``At this point we are not pursuing the research, because there are bigger problems to solve and we think this is only one approach to providing a source of cells.``

Stem Cell Sciences and Charlestown, Massachusetts-based BioTransplant Inc. (NasdaqNM:BTRN - news) confirmed they had applied to the European Patent Office for a patent on the process, but said Greenpeace had mischaracterized their work.

``The application shows that the firms have already transferred cell nuclei from human foetuses to egg cells from pigs and cultivated the resulting embryos for around a week in the laboratory,`` Greenpeace said in a statement.

``Society should not reward these Frankenstein scientists with patents,`` it added.

Mountford said his company had indeed used nuclear transfer to put a human cell nucleus into a pig`s egg. Nuclear transfer, the method used to create Dolly the sheep, the first cloned adult mammal, involves scraping the nucleus out of an egg cell and replacing it with the nucleus, which contains most of the genetic material, from another cell.

SOURCE OF STEM CELLS

The process, if done correctly, re-programmes the nucleus and it starts to divide as if it were a fertilised egg. In effect, it regresses back to the very first stages of life.

These cell masses could be a source of embryonic stem cells, which have the power to become any type of cell in the body at all, including nerve cells, blood cells or organ cells. Stem Cell Sciences said it had shown last month that this could be done, using mice.

In the latest case, Stem Cell Sciences, working with a team at Monash University, said it used a pig`s egg cell and the nucleus from a cell taken from a cell line, or laboratory culture of cells.

After the nuclear transfer the cells divided, 4 or 5 times, to create a mass of either 16 or 32 cells. Mountford said the experiment proved that human and animal cells could be fused for the purpose of therapeutic cloning.

Another company has done similar work. In 1998, Advanced Cell Technology, based in Worcester, Massachusetts, said its scientists had fused human cells into cow eggs and let them grow as an embryo for a few days. Its aim is also to produce organs and tissues for transplant.

The reason for using cow or pig eggs is simple -- they are more readily available than human eggs, which can be obtained only through difficult and painful surgery. Farm animal eggs are available at any slaughterhouse.

Julia Greenstein, chief scientific officer at BioTransplant, said her company had a long-standing arrangement to support and license Stem Cells` work.

``We are interested in Peter`s work in human cell reprogramming for human therapeutic cloning,`` she said. ``And we are interested in nuclear transfer for animal cloning.``

BioTransplant is also working on genetically engineered pigs as a potential source of animal-to-human transplants, or xenotransplants. Animals containing human genes, known as chimeras, are commonly used in medical science -- for instance, sheep that produce human proteins in their milk.

The U.S. government is forbidden by law to fund scientists who engage in cloning, therapeutic or otherwise, but privately funded scientists can legally do as they please.

Britain`s chief scientific officer has proposed that therapeutic cloning be legalised there, but the European Parliament condemned the idea in September. Australia is debating the issue.

[Cowboy00]

Hi Thorsten!

Ist ja alles ganz nett, aber findest Du das Klonen von Schweinsmenschen nicht niederträchtig? Die biotechnologische Errungenschaft der Genentschlüsselung in Ehren, sie machte uns zwei ja ein wenig reicher, aber das geht mir zu weit. Und denke daran ,ich bin sicher nicht konservativ eingestellt, sondern wie Du weisst gegenüber Genmanipulationen relativ offen! Was denkt dann erst ein alter Konservativer?

Gruß
Bernd

PS: Danke für den Antibiotikaartikel! Und meld Dich mal wieder!

[m.lynched]

Das "Klonen von Schweinsmenschen" liegt vielleicht im Rahmen des irgendwann Möglichen, ist aber nicht
das, worum es hier geht: Wie die aktuelle Ethik-Diskussion zeigt, wird das therapeutische Klonen möglicherweise
daran scheitern, daß kein Konsenz über die Verwendung menschlicher Embryos erzielt werden kann.
Also woher embryonale Stammzellen nehmen?
Wenn BTRN es schaffen sollte, hier einen adäquaten Ersatz auf Basis tierischer Embryos zu entwickeln, wäre
das ethische Dilemma (wann ist ein Mensch ein Mensch und darf man humane Embryos verwenden?) doch
außen vor! Nocheinmal die Kernaussage der letzten Pressemeldung:
They said they were looking for ways to advance therapeutic cloning, which would involve taking a patient`s own cells and growing them in the laboratory to create a source of stem cells or ``master cells,`` which could then be developed into tissue or organs for transplant.
Bei dem Vorhaben von Novartis und BioTransplant von vornherein auf Horrorvisionen abzustellen, zeugt in meinen
Augen von Unwissenheit und/oder Böswilligkeit, wenn man an die langen Wartelisten für Spenderorgane und
kriminellen Organhandel (vor allem in der dritten Welt) denkt. Über Stammzellen ist in den vergangenen Wochen
ja schon genug gesagt worden, so daß allen klar sein sollte, worum es hier geht: Nicht darum, Chimären zu
züchten und auszuweiden, sondern im Labor Organe aus Stammzellen heranwachsen zu lassen.

[Cowboy00]

@m.lynched:

Danke für die Anregung. Ich habe mir die Methoden näher angesehen, unter diesen Bedingungen scheint die Sache höchst interessant zu sein. Jedoch sind einige unwissende Anleger (wie Ich), die sich noch nicht informiert haben, sicher davon abgeschreckt worden, was in den großen Tageszeitungen stand. Für Deine Gegendarstellung danke ich Dir!


Gruß
Cowboy

[LeCorbusier]

hat jemand erfahrungen mit dem pusherblatt "CUTTING EDGE"?

in der neuesten ausgabe wird dort BIOTRANSPLANT als top pick empfohlen:

kaufkurs: unter 14€
kursziel: 22€
stoppkurs: 9,50€

institutioneller besitz: 40%
zu erschließen gilt es einen 2,5 bis 3 milliarden-dollar-markt

[asimon]

Was gibt es mittlerweile Neues von Biotransplant, ausser der beindruckenden Kursentwicklung auf 6.x.?

Ist die Atktie mittlerweile interessant, oder noch oder wieder?

Es wurde mich interessieren wie Ihr die Firma und deren Produkte einschätzt. Denn mittlerweile ist der Xenotransplantationsteil ausgeggliedert (Joint venture mit Novartis), die englische Konkurrenzfirma von Novartis eingestampft und die PERV Diskussion scheint doch eher beendet. Also wie schaut`s?

Ich gebe der Aktie aus verschiedenen Gründen ein mittelfristiges Kurspotential um die 12.X, also immerhin 100%, hauptsächlich wg. der Eligix Zelltrennung, der erteilten CE Zertifizierung und dem Novartis Joint venture.

Irgenwelche Meinungen?